← Back to patent-cliff list
TAN-118
Tier C — Watch / tradeTAN-118
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AHR
Indications (approved)：Inflammatory bowel disease
Regional status
US
Phase I
2024-10-01
EU
-
China
Phase II
2026-03-26
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of TAN-118?
Approved indications include: Inflammatory bowel disease.
When does the TAN-118 patent expire?
No public expiry year is available for TAN-118 yet; this page updates once verified.
How do I get a quote for TAN-118 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29